Thromb Haemost 2006; 96(06): 789-793
DOI: 10.1160/TH06-07-0393
Platelets and Blood Cells
Schattauer GmbH

Ethyl pyruvate exerts combined anti-inflammatory and anticoagulant effects on human monocytic cells

Marieke A. D. van Zoelen
1   Center for Infection and Immunity Amsterdam (CINIMA)
2   Center for Experimental and Molecular Medicine
,
Kamran Bakhtiari
3   Departments of Vascular Medicine
,
Mark C. Dessing
1   Center for Infection and Immunity Amsterdam (CINIMA)
2   Center for Experimental and Molecular Medicine
,
Cornelis van ’t Veer
1   Center for Infection and Immunity Amsterdam (CINIMA)
2   Center for Experimental and Molecular Medicine
,
C. Arnold Spek
1   Center for Infection and Immunity Amsterdam (CINIMA)
2   Center for Experimental and Molecular Medicine
,
Michael Tanck
4   Biostatistics; Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
,
Joost C. Meijers
3   Departments of Vascular Medicine
,
Tom van der Poll
1   Center for Infection and Immunity Amsterdam (CINIMA)
2   Center for Experimental and Molecular Medicine
› Author Affiliations
Financial support: This work was supported by Critical Therapeutic Inc., Lexington, Massachussetts, USA.
Further Information

Publication History

Received 13 July 2006

Accepted after resubmission 13 October 2006

Publication Date:
29 November 2017 (online)

Summary

Sepsis is characterized by a concurrent activation of inflammation and coagulation. Recently, recombinant human activated protein C was shown to decrease mortality in patients with severe sepsis presumably due to a combined anti-inflammatory and anticoagulant effect.These promising findings led to a search for other products that influence both the inflammatory and the procoagulant response to severe infection. Ethyl pyruvate (EP) was recently identified as an experimental anti-inflammatory agent during endotoxemia and sepsis. The aim of the present study was to investigate whether EP influences coagulation besides its anti-inflammatory effects. For this we investigated the effects of EP on the expression and function of tissue factor (TF), the principal initiator of coagulation activation in sepsis, in human monocytic (THP-1) cell cultures. EP dose-dependently inhibited the production of tumor necrosis factor (TNF)-α, macrophage inflammatory protein (MIP)-1α and MIP-1β by lipopolysaccharide (LPS)-stimulated THP-1 cells at mRNA and protein level, thereby confirming its anti-inflammatory properties in this in-vitro system.In addition, EP dose-dependently attenuated the increases in TF mRNA levels,TF-protein-surface expression and cell-surface-associated TF activity in LPS-stimulated THP-1 cells. These results demonstrate for the first time that EP is a compound with combined anti-inflammatory and anticoagulant effects.

 
  • References

  • 1 Bone RC, Grodzin CJ, Balk RA. Sepsis: a new hypothesis for pathogenesis of the disease process. Chest 1997; 112: 235-43.
  • 2 Levi M, Ten Cate H. Disseminated intravascular coagulation. N Engl J Med 1999; 341: 586-92.
  • 3 Bernard GR, Vincent JL, Laterre PF. et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699-709.
  • 4 Ulloa L, Ochani M, Yang H. et al. Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation. Proc Natl Acad Sci USA 2002; 99: 12351-6.
  • 5 Sims CA, Wattanasirichaigoon S, Menconi MJ. et al. Ringer's ethyl pyruvate solution ameliorates ischemia/reperfusion-induced intestinal mucosal injury in rats. Crit Care Med 2001; 29: 1513-8.
  • 6 Uchiyama T, Delude RL, Fink MP. Dose-dependent effects of ethyl pyruvate in mice subjected to mesenteric ischemia and reperfusion. Intensive Care Med 2003; 29: 2050-8.
  • 7 Tawadrous ZS, Delude RL, Fink MP. Resuscitation from hemorrhagic shock with Ringer's ethyl pyruvate solution improves survival and ameliorates intestinal mucosal hyperpermeability in rats. Shock 2002; 17: 473-7.
  • 8 Yang R, Gallo DJ, Baust JJ. et al. Ethyl pyruvate modulates inflammatory gene expression in mice subjected to hemorrhagic shock. Am J Physiol Gastrointest Liver Physiol 2002; 283: G212-21.
  • 9 Sappington PL, Fink ME, Yang R. et al. Ethyl pyruvate provides durable protection against inflammationinduced intestinal epithelial barrier dysfunction. Shock 2003; 20: 521-8.
  • 10 Song M, Kellum JA, Kaldas H. et al. Evidence that glutathione depletion is a mechanism responsible for the anti-inflammatory effects of ethyl pyruvate in cultured lipopolysaccharide-stimulated RAW 264.7 cells. J Pharmacol Exp Ther 2004; 308: 307-16.
  • 11 Han Y, Englert JA, Yang R. et al. Ethyl pyruvate inhibits nuclear factor-kappaB-dependent signaling by directly targeting p65. J Pharmacol Exp Ther 2005; 312: 1097-105.
  • 12 Maris NA, de Vos AF, Dessing MC. et al. Antiinflammatory effects of salmeterol after inhalation of lipopolysaccharide by healthy volunteers. Am J Respir Crit Care Med 2005; 172: 878-84.
  • 13 Ollivier V, Hammal S, Ameziane N. et al. Modulation of tissue factor expression by rapamycin and FK-506 in lipopolysaccharide-stimulated human mononuclear cells and serum-stimulated aortic smooth muscle cells. Thromb Haemost 2005; 94: 46-52.
  • 14 Bach RR. Tissue factor encryption. Arterioscler Thromb Vasc Biol 2006; 26: 456-61.
  • 15 Miyaji T, Hu X, Yuen PS. et al. Ethyl pyruvate decreases sepsis-induced acute renal failure and multiple organ damage in aged mice. Kidney Int 2003; 64: 1620-31.